{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:03:00Z","timestamp":1790197380592,"version":"4.1.0"},"reference-count":70,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,3,1]]},"DOI":"10.1001\/jamaoncol.2019.4659","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T16:31:11Z","timestamp":1576168271000},"page":"425","source":"Crossref","is-referenced-by-count":51,"title":["Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma"],"prefix":"10.1001","volume":"6","author":[{"given":"Francesco","family":"Maura","sequence":"first","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridgeshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Bolli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"},{"name":"Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Even H.","family":"Rustad","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts"},{"name":"Veterans Administration Boston Healthcare System, West Roxbury, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7239","key":"crv190007r1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome.","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"issue":"10","key":"crv190007r2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis.","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"issue":"13","key":"crv190007r3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"crv190007r4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma.","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"9","key":"crv190007r5","first-page":"2651","article-title":"Tumor heterogeneity and the biology of cancer invasion and metastasis.","volume":"38","author":"Fidler","year":"1978","journal-title":"Cancer Res"},{"issue":"10","key":"crv190007r6","first-page":"3174","article-title":"Heterogeneity of tumor cells from a single mouse mammary tumor.","volume":"38","author":"Dexter","year":"1978","journal-title":"Cancer Res"},{"issue":"20","key":"crv190007r7","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma.","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"22","key":"crv190007r8","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"10","key":"crv190007r9","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis.","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"crv190007r10","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"crv190007r11","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"crv190007r12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"26","key":"crv190007r13","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: time for a new definition?","volume":"122","author":"Dispenzieri","year":"2013","journal-title":"Blood"},{"key":"crv190007r14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.","volume":"2013","author":"Landgren","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"crv190007r15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"crv190007r16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma.","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"crv190007r17","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"18","key":"crv190007r18","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma.","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"crv190007r19","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"crv190007r20","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma.","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"crv190007r21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"crv190007r22","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"crv190007r23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications.","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"crv190007r24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma.","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"crv190007r25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"crv190007r26","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"crv190007r27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/ejh.2016.97.issue-6","article-title":"Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.","volume":"97","author":"Mikulasova","year":"2016","journal-title":"Eur J Haematol"},{"issue":"9","key":"crv190007r28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"crv190007r29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2011.060632","article-title":"Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.","volume":"98","author":"Schmidt-Hieber","year":"2013","journal-title":"Haematologica"},{"issue":"34","key":"crv190007r30","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"crv190007r31","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"crv190007r32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"20","key":"crv190007r33","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-07-0031","article-title":"Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.","volume":"13","author":"Brousseau","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"crv190007r34","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","article-title":"A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.","volume":"106","author":"Chng","year":"2005","journal-title":"Blood"},{"issue":"10","key":"crv190007r35","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells.","volume":"78","author":"van Nieuwenhuijzen","year":"2018","journal-title":"Cancer Res"},{"key":"crv190007r36","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"7339","key":"crv190007r37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma.","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"5","key":"crv190007r38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma.","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"1","key":"crv190007r39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"33","key":"crv190007r40","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"crv190007r41","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"crv190007r42","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma.","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"crv190007r43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"1","key":"crv190007r44","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma.","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"22","key":"crv190007r45","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.","volume":"1","author":"Mailankody","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"crv190007r46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"issue":"23","key":"crv190007r47","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"crv190007r48","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.","author":"Bolli","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"crv190007r49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"crv190007r50","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"crv190007r51","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","article-title":"Serial exome analysis of disease progression in premalignant gammopathies.","volume":"28","author":"Zhao","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"crv190007r52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability.","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"crv190007r53","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"crv190007r54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms.","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"crv190007r55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited.","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"crv190007r56","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression.","volume":"2012","author":"Manier","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"20","key":"crv190007r57","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma.","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"11","key":"crv190007r58","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"crv190007r59","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"crv190007r60","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma.","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"crv190007r61","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.","volume":"52","author":"D\u2019Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"crv190007r62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: a randomized study.","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"1","key":"crv190007r63","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.","volume":"118","author":"Mart\u00edn","year":"2002","journal-title":"Br J Haematol"},{"issue":"7","key":"crv190007r64","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/cncr.v113:7","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"crv190007r65","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma.","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"crv190007r66","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study.","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"crv190007r67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"crv190007r68","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"crv190007r69","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"crv190007r70","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma.","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2757387\/jamaoncology_maura_2019_rv_190007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T15:01:31Z","timestamp":1584025291000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2757387"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.4659","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}